enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Bristol Myers wins US FDA approval for new type of ...

   www.aol.com/news/us-fda-approves-bristol-myers...

   (Reuters) -The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the first new type of antipsychotic medicine in decades. The ...

3. Lumateperone - Wikipedia

   en.wikipedia.org/wiki/Lumateperone

   Lumateperone, sold under the brand name Caplyta, is an atypical antipsychotic medication of the butyrophenone class. It is approved for the treatment of schizophrenia as well as bipolar depression, as either monotherapy or adjunctive therapy (with lithium or valproate). [2] It is developed by Intra-Cellular Therapies, licensed from Bristol ...

4. List of antipsychotics - Wikipedia

   en.wikipedia.org/wiki/List_of_antipsychotics

   Antipsychotics by class Generic name Brand names Chemical class ATC code Typical antipsychotics; Acepromazine: Atravet, Acezine: phenothiazine: N05AA04

5. List of investigational antidepressants - Wikipedia

   en.wikipedia.org/wiki/List_of_investigational...

   This is a list of investigational antidepressants, or drugs that are currently under development for clinical use in the treatment of depression but are not yet approved. Specific indications include major depressive disorder, treatment-resistant depression, dysthymia, bipolar depression, and postpartum depression, among others.

6. FDA Approves First Fast-Acting Drug for Depression That ... - AOL

   www.aol.com/fda-approves-first-fast-acting...

   A new medication called Auvelity was just FDA-approved to treat major depressive disorder (MDD), also known as clinical depression, in as little as one week. The new “fast-acting” oral drug ...

7. Escitalopram (Lexapro): Everything You Need to Know Before ...

   www.aol.com/escitalopram-lexapro-everything-know...

   A few facts for you according to the folks from The Anxiety and Depression Association of America and the National Institute of Mental Health: In 2020, an estimated 14.8 million U.S. adults aged ...

8. Brilaroxazine - Wikipedia

   en.wikipedia.org/wiki/Brilaroxazine

   Brilaroxazine (developmental code name RP5063), also known as oxaripiprazole, [1] [2] is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of neuropsychiatric and inflammatory disorders. [3] [5] [6] [7] It has currently completed the first of two phase III clinical trials for ...

9. FDA approves standalone use of J&J’s ketamine-derived ... - AOL

   www.aol.com/fda-approves-standalone-j-j...

   The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the ...